C

Cresco Labs Inc
OTC:CRLBF

Watchlist Manager
Cresco Labs Inc
OTC:CRLBF
Watchlist
Price: 1.24 USD -3.13% Market Closed
Market Cap: 424.3m USD

Relative Value

The Relative Value of one CRLBF stock under the Base Case scenario is 3.05 USD. Compared to the current market price of 1.24 USD, Cresco Labs Inc is Undervalued by 59%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CRLBF Relative Value
Base Case
3.05 USD
Undervaluation 59%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
73
vs Industry
86
Median 3Y
1.1
Median 5Y
1.2
Industry
2.7
Forward
1
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-7.3
Industry
21.6
Forward
-8.1
vs History
38
vs Industry
51
Median 3Y
13.1
Median 5Y
14.3
Industry
16.9
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-1
Industry
22.9
vs History
63
vs Industry
73
Median 3Y
1.5
Median 5Y
1.8
Industry
2.3
vs History
77
vs Industry
70
Median 3Y
1.7
Median 5Y
1.9
Industry
3
Forward
1.6
vs History
79
vs Industry
70
Median 3Y
3.5
Median 5Y
4.1
Industry
5.6
vs History
68
vs Industry
48
Median 3Y
8.7
Median 5Y
14.2
Industry
13.4
Forward
6.8
vs History
63
vs Industry
44
Median 3Y
14.4
Median 5Y
23.5
Industry
16.7
Forward
14.4
vs History
38
vs Industry
42
Median 3Y
21.8
Median 5Y
22.7
Industry
16.1
vs History
6
vs Industry
30
Median 3Y
9.5
Median 5Y
-29.9
Industry
18.9
vs History
80
vs Industry
70
Median 3Y
1
Median 5Y
1.2
Industry
2

Multiples Across Competitors

CRLBF Competitors Multiples
Cresco Labs Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cresco Labs Inc
OTC:CRLBF
925m USD 1 -12.7 8.1 13.5
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
491.8B USD 5.3 19.6 16 20.8
CH
Roche Holding AG
SIX:ROG
271.4B CHF 4.4 28.8 12.2 14.3
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP 5.1 31.4 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
274.9B USD 4.3 14.4 10.2 12.1
CH
Novartis AG
SIX:NOVN
218.8B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.3 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.9B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
US
C
Cresco Labs Inc
OTC:CRLBF
Average P/E: 24.9
Negative Multiple: -12.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
Cresco Labs Inc
OTC:CRLBF
Average EV/EBITDA: 400.7
8.1
0%
N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
1%
11.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
C
Cresco Labs Inc
OTC:CRLBF
Average EV/EBIT: 1 713.6
13.5
28%
0.5
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5